Recent News

• 06.12.2025 - FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
• 06.10.2025 - Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
• 06.09.2025 - 46th Annual Goldman Sachs Global Healthcare Conference
• 06.03.2025 - Innoviva to Participate in Upcoming Investor Conferences
• 05.22.2025 - Patricia Drake
• 05.22.2025 - Marcie Cain
• 05.22.2025 - David Altarac, M.D.
• 05.22.2025 - Steve Basso
• 05.20.2025 - ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
• 05.07.2025 - Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Recent Filings

• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2025 - 8-K Current report
• 05.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.07.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2025 - 8-K Current report